Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press121310.36691/RJA1213ArticlesСтатьиResearch ArticleLong-term prophylaxis in HAE patientsДолгосрочная профилактика ангиоотеков у пациентов с НАОLatyshevaT VЛатышеваТВ V

доктор медицинских наук, профессор, зав. отделением иммунопатологии взрослых клиники

LatyshevaE AЛатышеваЕ А

кандидат медицинских наук, с.н.с. отделения иммунопатологии взрослых клиники

MantoI AМантоИ А

н.с., отделения иммунопатологии взрослых клиники

irina.manto@yandex.ruNRC Institute of Immunology FMBA of RussiaФГБУ «ГНЦ Институт иммунологии» ФМБА России15062019163VOL 16, NO3 (2019)ТОМ 16, №3 (2019)758302042020Copyright ©; 2019, Pharmarus Print MediaCopyright ©; 2019, Фармарус Принт Медиа2019Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/1213

Hereditary angioedema (HAE) due to of C1-inhibitor deficiency is a rare disease, which causes a strong physical and psychological impact on patients’ lives. HAE affects daily life, career opportunities, and social activity. In addition, fear of the edema development, as well as the associated with it pain and risk of death leads to depressive disorders specific for chronic (especially life-threatening) diseases. The emergence of modern pathogenetic drugs can minimize the effect of HAE and improve the patients’ quality of life. There are three different therapeutic strategies that are used for HAE treatment: long-term prophylaxis, short-term and on-demand therapy for acute attacks. This article focuses on long-term prophylaxis.

Наследственный ангиоотек (НАО) с дефицитом С1-ингибитора (С1-ИНГ) представляет собой редкое заболевание, которое оказывает сильное воздействие на жизнь пациентов как физически, так и эмоционально. Непредсказуемость атак влияет на повседневную жизнь, выбор профессии, социальную активность. Кроме того, страх перед развитием отека, а также связанными с ним болью и риском смерти приводит к депрессивным расстройствам, характерным для хронических, в особенности жизнеугрожающих заболеваний. Появление современных патогенетических препаратов способно минимизировать влияние НАО и улучшить качество жизни больных. В основе терапии НАО лежат долгосрочная профилактика, краткосрочная профилактика и купирование острых атак. В данной статье речь пойдет о долгосрочной профилактике.

hereditary angioedemaHAElong-term prophylaxisC1-inhibitorBerinertdanazolangioedemabradykininнаследственный ангиоотекНАОдолгосрочная профилактикаС1-ингибиторБеринертданазолангиоотекбрадикининАллергология и иммунология: национальное руководство. Под ред. Н.И. Ильиной и РМ. Хаитова. ГЭО-ТАР-Медиа. 2009:461-482Aygoren-Pursun E., Bygum A., Grivcheva-Panovska V. et al. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. N. Engl J. Med. 2018;379(4):352-362. DOI: 10.1056/NEJMoa1716995.Obtulowicz K. Bradykinin-mediated angioedema. Polish Arch Intern Med. 2016;126(1-2):76-85. DOI: 10.20452/pamw.3273.Bas M., Adams V., Suvorava T., Niehues T., Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy. 2007;62(8):842-856. DOI: 10.1111/j.1398-9995.2007.01427.x.Davis A., Lu F., Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost. 2010;104(11):886-893. DOI: 10.1160/TH10-01-0073.Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy. 2014;6(5):533-551. DOI: 10.2217/imt.14.33.Kaplan AP, Joseph K. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade. Immunol Allergy Clin North Am. 2017;37(3):513-525. DOI: 10.1016/j. iac.2017.04.001.Caccia S., Suffritti C., Cicardi M. Pathophysiology of Hereditary Angioedema. Pediatr Allergy Immunol Pulmonol. 2014;27(4):159-163. DOI: 10.1089/ped.2014.0425.Germenis AE, Speletas M. The Genetics of Hereditary Angioedema the Iceberg Slowly Emerges. J. Angioedema. 2016;2(1):8-17.Germenis AE, Speletas M. Genetics of Hereditary Angioedema Revisited. Clin Rev Allergy Immunol. 2016;51(2):170-182. DOI: 10.1007/s12016-016-8543-x.Maurer M., Magerl M., Ansotegui I. et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575-1596. DOI: 10.1111/all.13384.Bork K., Aygoren-Pursun E., Bas M. et al. Guideline: Hereditary angioedema due to C1 inhibitor deficiency: S1 Guideline of the German Society for Angioedema (Deutsche Gesellschaft fur Angioodeme, DGA), German Society for Internal Medicine (Deutsche Gesellschaft fur Innere Medizin, DGIM), German S. Allergo J. Int. 2019;28(1):16-29. DOI: 10.1007/s40629-018-0088-5.Caballero T., Baeza ML, Cabanas R. et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J. Investig Allergol Clin Immunol. 2011;21(5):333-347; quiz follow 347.Латышева ТВ, Латышева ЕА, Мартынова ИА. Оказание неотложной медицинской помощи пациентам с ангиоотеками, индуцированными брадикинином. Медицинский алфавит. 2017;5:33-39Cicardi M., Suffritti C., Perego F., Caccia S. Novelties in the diagnosis and treatment of angioedema. J. Investig Allergol Clin Immunol. 2016;26(4):212-221. DOI: 10.18176/jiaci.0087.Maia LSM, Moreno AS, Ferriani MPL et al. Genotype-phenotype correlations in Brazilian patients with hereditary angioedema due to C1 inhibitor deficiency. Allergy Eur J. Allergy Clin Immunol. 2019;74(5):1013-1016. DOI: 10.1111/ all.13699.Bork K., Murat EA, Tilo B. et al. Guideline: Hereditary angioedema due to C1 inhibitor deficiency S1 Guideline of the German Society for Angioedema (Deutsche Gesellschaft fur Angioodeme, DGA), German Society for Internal Medicine (Deutsche Gesellschaft fur Innere Medizin, DGIM ), Ge. 2019:16-29. DOI: 10.1007/s40629-018-0088-5.Borum ML, Ali MA. Hereditary angioedema: what the gastroenterologist needs to know. Clin Exp Gastroenterol. 2014;20(7):435-445. DOI: 10.2147/CEG.S50465.Rubinstein E., Stolz LE, Sheffer AL, Stevens C., Bousvaros A. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterol. 2014;14(1):71. DOI: 10.1186/1471-230X-14-71.Bork K., Hardt J., Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J. Allergy Clin Immunol. 2012;130(3):692-697. DOI: 10.1016/j. jaci.2012.05.055.Zotter Z, Csuka D, Szabo E et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9(1):44. DOI: 10.1186/17501172-9-44.Maurer M., Magerl M. Hereditary angioedema: an update on available therapeutic options. JDDG J. der Dtsch Dermatologischen Gesellschaft. 2010;8(9):663-672. DOI: 10.1111/j.1610-0387.2010.07450.x.Caballero T., Baeza ML, Cabanas R. et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J. Investig Allergol Clin Immunol. 2011;21(6):422-441.Bowen T., Cicardi M., Farkas H. et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J. Allergy Clin Immunol. 2004;114(3):629-637. DOI: 10.1016/j.jaci.2004.06.043.Maurer M., Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. J. Dtsch Dermatol Ges. 2011;9(2):99-107. DOI: 10.1111/j.1610-0387.2010.07546.x.Craig T. Busse P., Gower RG et al. Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. Ann Allergy, Asthma Immunol. 2018;121(6):673-679. DOI: 10.1016/j.anai.2018.07.025.Henry Li H., Riedl M., Kashkin J. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. Clin Rev Allergy Immunol. 2019;56(2):207-218. DOI: 10.1007/ s12016-018-8684-1.Greve J., Strassen U., Gorczyza M. et al. Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency. JDDG J. der Dtsch Dermatologischen Gesellschaft. 2016;14(3):266-275. DOI: 10.1111/ddg.12856.Li HH, Mycroft S., Christiansen S. et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial. Allergy Asthma Proc. 2018;39(5):365-370. DOI: 10.2500/aap.2018. 39.4164.Maitrot-Mantelet L., Agopian A., Gompel A. Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill. Horm Mol Biol Clin Investig. 2010;3(3):441-447. DOI: 10.1515/HMBCI.2010.062.Bouillet L., Lehmann A., Gompel A., Boccon-Gibod I., Launay D., Fain O. Traitements des angiredemes hereditaires: Recommandations du centre de reference national des an-giredemes (consensus 2014de Bordeaux). In French Press Med-icale. 2015;44(5):526-532. DOI: 10.1016/j.lpm.2015.01.005.Longhurst HJ. Hereditary and other orphan angioede-mas: A new prophylactic option at last? Clin Exp Allergy. 2013;43(4):380-382. DOI: 10.1111/cea.12088.Saule C., Boccon-Gibod I., Fain O. et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013;43(4):475-482. DOI: 10.1111/cea.12055.Caballero T., Farkas H., Bouillet L. et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J. Allergy Clin Immunol. 2012;129(2):308-320. DOI: 10.1016/j.jaci.2011.11.025.Bork K., Bygum A., Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy, Asthma Immunol. 2008;100(2):153-161. DOI: 10.1016/S1081-1206(10)60424-3.Banerji A., Sloane DE, Sheffer AL. Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S19-22.Sabharwal G., Craig T. Pediatric hereditary angioedema: an update. F1000Research. 2017;6(0):1205. DOI: 10.12688/ f1000research.11320.1.Bouillet L., Gompel A. Hereditary Angioedema in Women. Specific Challenges. Immunol Allergy Clin North Am. 2013;33(4):505-511. DOI: 10.1016/j.iac.2013.07.006.Bowen T., Cicardi M., Farkas H. et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy, Asthma Clin Immunol. 2010;6(1):24. DOI: 10.1186/1710-1492-6-24.Farkas H., Martinez-Saguer I., Bork K. et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy Eur J. Allergy Clin Immunol. 2017;72(2):300-313. DOI: 10.1111/all.13001.Frank MM, Zuraw B., Banerji A. et al. Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency. Pediatrics. 2016;138(5):e20160575. DOI: 10.1542/ peds.2016-0575.Donaldson VH, Evans RR. A biochemical abnormality in Herediatry angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J. Med. 1963;35:37-44. DOI: 10.1016/0002-9343(63)90162-1.Brackertz D., Kueppers F. Hereditary angioneurotic oedema. Lancet (London, England). 1973;2(7830):680. DOI: 10.1016/ s0140-6736(73)92519-1.Craig T., Shapiro R., Vegh A. et al. Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema. Allergy Rhinol (Providence). 2017;8(1):13-19. DOI: 10.2500/ar.2017.8.0192.Bork K., Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J. Allergy Clin Immunol. 1989;83(3):677-682. DOI: 10.1016/0091-6749(89)90082-1.Riedl MA, Bygum A., Lumry W. et al. Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. J. Allergy Clin Immunol Pract. 2016;4(5):963-971. DOI: 10.1016/j.jaip.2016.04.018.Busse P., Baker J., Martinez-Saguer I. et al. Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. J. Allergy Clin Immunol Pract. 2017;5(4):1142-1145. DOI: 10.1016/j.jaip.2016.12.033.Fox J., Vegh AB, Martinez-Saguer I. et al. Safety ofa C1-inhibitor concentrate in pregnant women with hereditary angioedema. Allergy Asthma Proc. 2017;38(3):216-221. DOI: 10.2500/ aap.2017.38.4038.Bygum A., Martinez-Saguer I., Bas M. et al. Use of a C1 Inhibitor Concentrate in Adults >65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry. Drugs and Aging. 2016;33(11):819-827. DOI: 10.1007/s40266-016-0403-0.Bork K., Hardt J. Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week. Int Arch Allergy Immunol. 2011;154(1):81-88. DOI: 10.1159/000319213.Martinez-Saguer I, Cicardi M, Suffritti C et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcuta neous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 2014;54(6):1552-1561. DOI: 10.1111/trf.12501.Zuraw BL, Cicardi M, Longhurst HJ et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy. 2015;70(10):1319-1328. DOI: 10.1111/all.12658.Longhurst H, Cicardi M, Craig T et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med. 2017;376(12):1131-1140. DOI: 10.1056/ NEJMoa1613627.Bouillet L, Longhurst H, Boccon-Gibod I et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484.e1-484.e4. DOI: 10.1016/j. ajog.2008.04.034.